Primer İmmün Yetmezlik Tanısıyla Subkutan İmmünglobülin Alan Hastalarımızın Klinik İzlemi

Hulya ANIL; Koray HARMANCİ; Müge AKYÜZ

Makale detayları

Primer İmmün Yetmezlik Tanısıyla Subkutan İmmünglobülin Alan Hastalarımızın Klinik İzlemi

Yazarlar:

Hulya ANIL | Koray HARMANCİ | Müge AKYÜZ

Yayıncı:

Eskişehir Osmangazi University

Ana Başlıklar:

Sağlık teşvikleri

Dergi:

Osmangazi Journal of Medicine 2020 Vol.42 Issue 6, pp.665-669

Belge Tipi:

Makale

Yayın Tarihi:

11/2020

Belge Dili:

Türkçe

Document ID (Org No.):

2000555151

Sıklık:

İki Aylık

eISSN:

2587-1579

pISSN:

1305-4953

Özet:

 


In primary immunodeficiencies, immunoglobulin therapy is applied to prevent infections.In recent years, subcutaneous treatment is preferred instead of intravenously.In this study, demographic and clinical characteristics of patients who underwent subcutaneous immunoglobulin treatment due to primary immunodeficiency in our center were given. The records of patients who underwent subcutaneous treatment with the diagnosis of primary immunodeficiency between 2014-2017 in Eskişehir Osmangazi University Faculty of Medicine Pediatric Allergy and Immunology clinic were analyzed retrospectively. 15 patients with primary immunodeficiency were included in the study.9 (60%) of the patients were male, their ages were determined as the lowest 10 months - highest 15 years.Ataxia telangiectasia in three patients (20%), common variable immune deficiency in three (20%), X-linked agamaglobulinemia in three (20%), autosomal recessive agamaglobulinemia in one (6.6%), unclassified hypogamaglobulinemia in two (13.2%), transient hypogamaglobulinemia in one (6.6%), hyper IgE syndrome  in one (6.6%) ,and hyper IgM syndrome in one (6.6%)  detected.Two of the three  patients (66.6%) who were followed with ataxia telangiectasia were hospitalized due to the infection they had in the first year of subcutaneous immunoglobulin treatment.During the 2-year follow-up period of other patients, no infection requiring hospitalization was recorded. All patients stated that they would prefer subcutaneous treatment in their follow-up.Consequently, subcutaneous immunoglobulin therapy is an effective, easy and safe option.

.

Makale detayları

Primer İmmün Yetmezlik Tanısıyla Subkutan İmmünglobülin Alan Hastalarımızın Klinik İzlemi

Yazarlar: Hulya ANIL | Koray HARMANCİ | Müge AKYÜZ

Yayıncı: Eskişehir Osmangazi University

Ana Başlıklar: Sağlık teşvikleri

Dergi: Osmangazi Journal of Medicine 2020 Vol.42 Issue 6, pp.665-669

Belge Tipi: Makale

Yayın Tarihi: 11/2020

Belge Dili: Türkçe

Document ID (Org No.): 2000555151

Sıklık: İki Aylık

eISSN: 2587-1579

pISSN: 1305-4953

Sayı

Yazarlar:

Hulya ANIL | Koray HARMANCİ | Müge AKYÜZ

Yayıncı:

Eskişehir Osmangazi University

Ana Başlıklar:

Sağlık teşvikleri

Dergi:

Osmangazi Journal of Medicine 2020 Vol.42 Issue 6, pp.665-669

Belge Tipi:

Makale

Yayın Tarihi:

11/2020

Belge Dili:

Türkçe

Document ID (Org No.):

2000555151

Sıklık:

İki Aylık

eISSN:

2587-1579

pISSN:

1305-4953